Search Results

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari®.

Emmaus Life Sciences, Inc. today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® in the country to treat sickle cell disease in patients five years of age and older.

Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program by $10 million annually, aiding job creation in the state.

Emmaus Life Sciences, Inc., a leader in sickle ell disease treatment, announced preliminary results for the 3 months ended March 31, 2023.